Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2018

Revenue Recognition

Schedule of disaggregation of revenue by test families

	Year Ended December 31,
	2018		2017		2016
(Amounts in thousands)			(As Revised)		(As Revised)
Sales of genetic tests
Panorama NIPT	$	140,932	$	128,896	$	140,582
HCS		87,171		63,467		56,417
Other genetic tests		12,263		11,414		12,407
Product revenues		240,366		203,777		209,406
Licensing and other
Constellation		4,844		4,229		3,106
Qiagen		5,794		—		—
Other		6,650		1,619		—
Licensing and other revenues		17,288		5,848		3,106
Total revenues	$	257,654	$	209,625	$	212,512

Schedule of disaggregation of revenue by payer types

	Year Ended December 31,
	2018		2017		2016
(Amounts in thousands)			(As Revised)		(As Revised)
Insurance carriers	$	193,895	$	163,861	$	157,570
Laboratory partners		44,062		36,001		46,129
Patients		19,697		9,763		8,813
Total revenues	$	257,654	$	209,625	$	212,512

Schedule of total revenue by geographic area

	Year ended December 31,
	2018		2017		2016
(Amounts in thousands)			(As Revised)		(As Revised)
United States	$	225,931	$	185,533	$	188,492
Americas, excluding U.S.		3,472		3,028		2,562
Europe, Middle East, India, Africa		20,866		13,998		14,256
Other		7,385		7,066		7,202
Total	$	257,654	$	209,625	$	212,512

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at		Balance at
	December 31,		December 31,
	2018		2017
(Amounts in thousands)			(As Revised)
Assets:
Accounts receivable	$	62,223	$	44,089
Liabilities:
Deferred revenue, current portion	$	4,131	$	1,420
Deferred revenue, long-term portion		40,058		—
Total deferred revenues	$	44,189	$	1,420

Schedule of changes in the balance of deferred revenues

	Deferred
	Revenues
	(in thousands)
Balance at December 31, 2017	$	1,420
Increase in deferred revenues		43,481
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(712)
Balance at December 31, 2018	$	44,189